5 results on '"Hendrika Adriana Linda Kievit"'
Number of results to display per page
Search Results
2. Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study
- Author
-
Montserrat Figueira, K R Nielsen, Luciano Sanroman, Ebbe Langholz, Hillel Vardi, Selwyn Odes, Daniela Lazăr, Fernando Magro, Laszlo Lakatos, Riina Salupere, I. Kaimakliotis, Carlos Gonzalez-Portela, Juan-Ramon Pineda, Emma Whitehead, Michael Friger, Niels Thorsgaard, Katherine Ashton, Petra Weimers, Irena Valantiene, Hendrika Adriana Linda Kievit, Vibeke Andersen, Jesús Martínez-Cadilla, Pia Munkholm, Konstantinos H. Katsanos, Peterne Demenyi, Jóngerð Maria Miné Midjord, Karen Kudsk, Adrian Goldis, Jose-Ignacio Rodriguez-Prada, Renata D'Incà, Ruta Kucinskiene, Gediminas Kiudelis, Dimitrios Politis, Pekka Collin, Jens Kjeldsen, M. Giannotta, David Martinez Ares, Corinne Gower-Rousseau, Milan Lukas, Laimas Virginijus Jonaitis, Amalia Carmona, Clays Aalykke, Carl Eriksson, Juozas Kupcinskas, Szabina Nemethne Kramli, Katrine Carlsen, Ulla-Britt Widen, Svetlana Turcan, Martin Bortlik, Birgitte Blichfeldt, Luísa Castro, Zeljko Krznaric, Dana Duricova, Natalia Pedersen, Karina Winther Andersen, Zsuzsanna Vegh, Limas Kupčinskas, Romanas Zykus, Johan Burisch, Alessandro Sartini, Pierre Ellul, Santos Pereira, Vicent Hernandez, V Domislović, Jonas Halfvarson, G. Girardin, Naila Arebi, A. Santini, Alberto Fernandez, Shaji Sebastian, Sally Myers, Doron Schwartz, D. Valpiani, Luísa Barros, Alexandros Skamnelos, Dorte Marker, Stefania Chetcuti Zammit, Silvija Čuković-Čavka, Mathurin Fumery, Jens Frederik Dahlerup, Peter L. Lakatos, Pia Oksanen, Inna Nikulina, Nikša Turk, Anastasia Nicolaou, Dimitrios K. Christodoulou, Elena Belousova, Ida Vind, Olga Shonová, Giualia Dal Piaz, Registre EPIMAD, CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Amiens-Picardie-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), IBD clinical and research centre, ISCARE, Prague, Czech Republic, Service Psychiatrie de l'Enfant et de l'Adolescent, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Robert Debré, School of Medicine, University of Zagreb, Hull and East Yorkshire Eye Hospital, Madeira Interactive Technologies Institute (M-ITI), Hospital de São João [Porto], Timisoara Hospital [Timisoara, Romania], Dept of Medicine, Div of Gastroenterology, Örebro University Hospital [Örebro, Sweden], Macquarie University, University of Copenhagen = Københavns Universitet (UCPH), Lithuanian University of health Sciences [Kaunas], CHU Amiens-Picardie, Périnatalité et Risques Toxiques - UMR INERIS_I 1 (PERITOX), Institut National de l'Environnement Industriel et des Risques (INERIS)-Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, Service d'Epidémiologie et de Santé Publique [Lille], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Institute for Translational Research in Inflammation - U 1286 (INFINITE (Ex-Liric)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), and Semmelweis University [Budapest]
- Subjects
Adult ,Male ,medicine.medical_specialty ,[SDV]Life Sciences [q-bio] ,Disease ,Inflammatory bowel disease ,03 medical and health sciences ,Indirect costs ,0302 clinical medicine ,Crohn Disease ,Internal medicine ,Health care ,medicine ,Humans ,Prospective Studies ,Prospective cohort study ,Diagnostic Techniques and Procedures ,Digestive System Surgical Procedures ,Biological Products ,Hepatology ,business.industry ,Gastroenterology ,Health Care Costs ,Middle Aged ,medicine.disease ,Ulcerative colitis ,digestive system diseases ,Europe ,Hospitalization ,030220 oncology & carcinogenesis ,Cohort ,Population study ,na ,Colitis, Ulcerative ,Female ,030211 gastroenterology & hepatology ,business ,Follow-Up Studies - Abstract
BACKGROUND: Inflammatory bowel disease (IBD) places a significant burden on health-care systems because of its chronicity and need for expensive therapies and surgery. With increasing use of biological therapies, contemporary data on IBD health-care costs are important for those responsible for allocating resources in Europe. To our knowledge, no prospective long-term analysis of the health-care costs of patients with IBD in the era of biologicals has been done in Europe. We aimed to investigate cost profiles of a pan-European, community-based inception cohort during 5 years of follow-up.METHODS: The Epi-IBD cohort is a community-based, prospective inception cohort of unselected patients with IBD diagnosed in 2010 at centres in 20 European countries plus Israel. Incident patients who were diagnosed with IBD according to the Copenhagen Diagnostic Criteria between Jan 1, and Dec 31, 2010, and were aged 15 years or older the time of diagnosis were prospectively included. Data on clinical characteristics and direct costs (investigations and outpatient visits, blood tests, treatments, hospitalisations, and surgeries) were collected prospectively using electronic case-report forms. Patient-level costs incorporated procedures leading to the initial diagnosis of IBD and costs of IBD management during the 5-year follow-up period. Costs incurred by comorbidities and unrelated to IBD were excluded. We grouped direct costs into the following five categories: investigations (including outpatient visits and blood tests), conventional medical treatment, biological therapy, hospitalisation, and surgery.FINDINGS: The study population consisted of 1289 patients with IBD, with 1073 (83%) patients from western Europe and 216 (17%) from eastern Europe. 488 (38%) patients had Crohn's disease, 717 (56%) had ulcerative colitis, and 84 (6%) had IBD unclassified. The mean cost per patient-year during follow-up for patients with IBD was €2609 (SD 7389; median €446 [IQR 164-1849]). The mean cost per patient-year during follow-up was €3542 (8058; median €717 [214-3512]) for patients with Crohn's disease, €2088 (7058; median €408 [133-1161]) for patients with ulcerative colitis, and €1609 (5010; median €415 [92-1228]) for patients with IBD unclassified (pINTERPRETATION: Overall direct expenditure on health care decreased over a 5-year follow-up period. This period was characterised by increasing expenditure on biologicals and decreasing expenditure on conventional medical treatments, hospitalisations, and surgeries. In light of the expenditures associated with biological therapy, cost-effective treatment strategies are needed to reduce the economic burden of inflammatory bowel disease.FUNDING: Kirsten og Freddy Johansens Fond and Nordsjællands Hospital Forskningsråd.
- Published
- 2020
- Full Text
- View/download PDF
3. 742 DISCONTINUATION OF INFLIXIMAB THERAPY IN PATIENTS WITH CROHN'S DISEASE IN SUSTAINED, COMPLETE CLINICAL-BIOCHEMICAL-ENDOSCOPIC REMISSION: A DOUBLE-BLINDED, PLACEBO-CONTROLLED, RANDOMIZED CLINICAL TRIAL
- Author
-
Svetlana Meisner, Jørgen Jahnsen, Ida Vind, Klaus Bendtzen, Maria Dorn-Rasmussen, Lars Martinsen, Niels Thorsgaard, Sven Almer, Hendrika Adriana Linda Kievit, Jane Moeller, Sine Buhl, Taina Sipponen, Akbar Molazahi, Eva E. Dahl, Jens Kjeldsen, Mark A. Ainsworth, Katrine R. Christensen, Casper Steenholdt, Jens Frederik Dahlerup, Jan Marsal, Synn⊘ve L. Aure, J⊘rn Brynskov, Ole Østergaard Thomsen, Natalia Pedersen, Tobias Wirenfeldt Klausen, J⊘rgen Steen Agnholt, and Annett G. Cannon
- Subjects
medicine.medical_specialty ,education.field_of_study ,Crohn's disease ,Hepatology ,business.industry ,Population ,Gastroenterology ,medicine.disease ,Placebo ,Infliximab ,Discontinuation ,law.invention ,Maintenance therapy ,Randomized controlled trial ,law ,Internal medicine ,Multicenter trial ,medicine ,education ,business ,medicine.drug - Abstract
Background It remains unknown whether infliximab (IFX) successfully can be discontinued once Crohn's disease (CD) patients have attained sustained, complete clinical, biochemical, and endoscopic remission. No randomized, placebo (PBO) controlled trial has previously assessed this. Methods This double-blind, randomized, PBO-controlled multicenter trial enrolled patients with luminal CD who had been treated with standard IFX maintenance therapy for at least 1 year, in complete remission at the time of inclusion defined as CD Activity Index (CDAI) 150 with an increase in CDAI >70-point from baseline over two consecutive weeks; or definitive clinical relapse requiring immediate intervention as judged by treating physician) in the intention-to-treat population. Results The study population comprised 115 patients (n=54 female; age median 34 years [IQR 26-50]; disease duration median 6 years [3-12]; IFX treatment duration median 23 months [16-39]). All patients were in combined clinical- (CDAI median 41 [IQR 15-66]), biochemical- (CRP median 3mg/L [IQR 2-4]), and endoscopic- (Simple Endoscopic Score for CD median 0, [IQR 0-0] (n=99)) remission. Patients were randomized to continued IFX therapy (n=59) or to start PBO infusions (n=56) (Figure 1). Time to relapse was significantly shorter among patients who discontinued IFX as compared to those continuing IFX (p 150) the figures were 47% in the PBO group vs. 98% in IFX group (p Conclusion This first double-blinded placebo-controlled RCT of IFX withdrawal in Crohn's disease patients strongly suggests that discontinuation of IFX leads to a considerable risk of relapse despite combined clinical, biochemical, and endoscopic remission. Download : Download high-res image (53KB) Download : Download full-size image Download : Download high-res image (56KB) Download : Download full-size image
- Published
- 2021
- Full Text
- View/download PDF
4. Natural Disease Course of Ulcerative Colitis During the First Five Years of Follow-up in a European Population-based Inception Cohort-An Epi-IBD Study
- Author
-
Selwyn Odes, Riina Salupere, Pekka Collin, Konstantinos H. Katsanos, Dana Duricova, Hendrika Adriana Linda Kievit, I. Kaimakliotis, Jóngerð Midjord, Dimitrios K. Christodoulou, Johan Burisch, Carl Eriksson, Luísa Castro, Ebbe Langholz, Vibeke Andersen, Jonas Halfvarson, Pierre Ellul, Naila Arebi, Pia Oksanen, Pia Munkholm, Shaji Sebastian, K R Nielsen, Elena Belousova, Renata D'Incà, Inna Nikulina, Jens Kjeldsen, Marko Brinar, Limas Kupčinskas, Vicent Hernandez, Gediminas Kiudelis, Karina Winther Andersen, Zsuzsanna Vegh, Alina Toca, Corinne Gower-Rousseau, Svetlana Turcan, Martin Bortlik, Adrian Goldis, Natalia Pedersen, Mathurin Fumery, Peter L. Lakatos, Fernando Magro, Silvija Čuković-Čavka, Ravi Misra, Stefania Chetcuti Zammit, Doron Schwartz, D. Valpiani, Luísa Barros, Sally Myers, University of Copenhagen = Københavns Universitet (UCPH), University Hospital of Ioannina, Centro Hospitalar Universitário de São João [Porto], Universidade do Porto = University of Porto, Odense University Hospital (OUH), Semmelweis University [Budapest], McGill University Health Center [Montreal] (MUHC), Örebro University, CHU Amiens-Picardie, Registre EPIMAD, CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Amiens-Picardie-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service d'Epidémiologie et de Santé Publique [Lille], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Institute for Translational Research in Inflammation - U 1286 (INFINITE (Ex-Liric)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), University Hospital Centre Zagreb, Partenaires INRAE, University of Zagreb, Moscow Regional Research Clinical Institute (MONICA), Hull and East Yorkshire Eye Hospital, Lithuanian University of health Sciences [Kaunas], Ben-Gurion University of the Negev (BGU), G.B. Morgagni-Pierantoni Hospital [Forlì, Italy], Università degli Studi di Padova = University of Padua (Unipd), University of Tartu, Mater Dei Hospital [Malta], ISCARE, Charles University [Prague] (CU), Victor Babeş University of Medicine and Pharmacy (UMFT), University research clinic [Herning, Denmark], State University of Moldova, National Hospital of the Faroe Islands [Tórshavn, Faroe Islands], Viborg Hospital, Regional Hospital West Jutland [Denmark], University of Southern Denmark (SDU), St Mark's Hospital, Tampere University Hospital, University of Tampere [Finland], and Instituto de Investigación Sanitaria Galicia Sur [Vigo, Spain]
- Subjects
Adult ,Male ,medicine.medical_specialty ,medicine.medical_treatment ,[SDV]Life Sciences [q-bio] ,Population ,Inflammatory bowel disease ,surgery ,03 medical and health sciences ,0302 clinical medicine ,Gastrointestinal Agents ,Internal medicine ,medicine ,Humans ,Immunologic Factors ,biologics ,Prospective Studies ,Prospective cohort study ,education ,Colectomy ,education.field_of_study ,treatment ,business.industry ,hospitalisation ,Hazard ratio ,Gastroenterology ,General Medicine ,Middle Aged ,medicine.disease ,Ulcerative colitis ,Europe ,Hospitalization ,030220 oncology & carcinogenesis ,Cohort ,Disease Progression ,030211 gastroenterology & hepatology ,Colitis, Ulcerative ,Female ,prognosis ,business ,Cohort study ,Follow-Up Studies - Abstract
Background and Aims: Few population-based cohort studies have assessed the disease course of ulcerative colitis [UC] in the era of biological therapy and widespread use of immunomodulators. The aim of this study was to assess the 5-year outcome and disease course of patients with UC in the Epi-IBD cohort.Methods: In a prospective, population-based inception cohort of unselected patients with UC, patients were followed up from the time of their diagnosis, which included the collection of their clinical data, demographics, disease activity, medical therapy, and rates of surgery, cancers, and deaths. Associations between outcomes and multiple covariates were analysed by Cox regression analysis.Results: A total of 717 patients were included in the study. During follow-up, 43 [6%] patients underwent a colectomy and 163 [23%] patients were hospitalised. Of patients with limited colitis [distal to the left flexure], 90 [21%] progressed to extensive colitis. In addition, 92 [27%] patients with extensive colitis experienced a regression in disease extent, which was associated with a reduced risk of hospitalisation (hazard ratio [HR]: 0.5 95% CI: 0.3-0.8]. Overall, patients were treated similarly in both geographical regions; 80 [11%] patients needed biological therapy and 210 [29%] patients received immunomodulators. Treatment with immunomodulators was found to reduce the risk of hospitalisation [HR: 0.5 95% CI: 0.3-0.8].Conclusions: Although patients in this population-based cohort were treated more aggressively with immunomodulators and biological therapy than in cohorts from the previous two decades, their disease outcomes, including colectomy rates, were no different. However, treatment with immunomodulators was found to reduce the risk of hospitalisation.
- Published
- 2018
- Full Text
- View/download PDF
5. OP15 Cost analysis in a prospective European population-based inception cohort: is there a cost-saving effect of biological therapy?
- Author
-
Svetlana Turcan, Ebbe Langholz, Pia Oksanen, Zeljko Krznaric, Elena Belousova, D. Valpiani, I. Kaimakliotis, Limas Kupčinskas, Naila Arebi, Pia S. Munkholm, Vibeke Andersen, Péter Lakatos, Niels C Pedersen, Epi-IBD, Hillel Vardi, Shmuel Odes, K.H. Katsanos, K R Nielsen, Zsuzsanna Vegh, Renata D'Incà, Shaji Sebastian, Dana Duricova, Dagan Schwartz, Johan Burisch, Jonas Halfvarson, Jens Frederik Dahlerup, Pierre Ellul, Riina Salupere, Mathurin Fumery, Hendrika Adriana Linda Kievit, Fernando Magro, Adrian Goldis, Vicent Hernandez, and M. Giannotta
- Subjects
0301 basic medicine ,business.industry ,Gastroenterology ,General Medicine ,European population ,INCEPTION COHORT ,Cost savings ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Environmental health ,Cost analysis ,Medicine ,030211 gastroenterology & hepatology ,business ,health care economics and organizations - Abstract
Cost analysis in a prospective European population-based inception cohort : is there a cost-saving effect of biological therapy?
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.